1. Abraham, E. P., & Chain, E. (1940). An enzyme from bacteria able to destroy penicillin. Nature, 146, 837.
2. Aminov, R. I. (2009). The role of antibiotics and antibiotic resistance in nature. Environmental Microbiology, 11, 2970â2988.
3. Aminov, R. I., & Mackie, R. I. (2007). Evolution and ecology of antibiotic resistance genes. FEMS Microbiology Letters, 271, 147â161.
4. Armelagos, G. J. (1969). Disease in ancient Nubia. Science, 163, 225â258.
5. Bassett, E. J., Keith, M. S., Armelagos, G. J., Martin, D. L., & Villanueva, A. R. (1980). Tetracycline-labeled human bone from ancient Sudanese Nubia (A.D. 350). Science, 209, 1532â1534.
6. Beaber, J. W., Hochhut, B., & Waldor M. K. (2004). SOS response promotes horizontal dissemination of antibiotic resistance genes. Nature, 427, 72â74.
7. Bengtsson, B., & Wierup, M. (2006). Antimicrobial resistance in Scandinavia after ban of antimicrobial growth promoters. Animal Biotechnology, 17, 147â156.
8. Bush, K., & Macielag, M. J. (2010). New ÎČ-lactam antibiotics and ÎČ-lactamase inhibitors. Expert Opinion on Therapeutic Patents, 20, 1277â1293.
9. Cha, J. Y., Ishiwata, A., & Mobashery, S. (2004). A novel ÎČ-lactamase activity from a penicillin-binding protein of Treponema pallidum and why syphilis is still treatable with penicillin. Journal of Biological Chemistry, 279, 14917â14921.
10. Chain, E., Florey, H. W., Gardner, A. D., Heatley, N. G., Jennings, M. A., Orr-Ewing, J., & Sanders, A. G. (2005). The classic: penicillin as a chemotherapeutic agent. 1940. Clinical Orthopaedics and Related Research, 439, 23â26.
11. Chee-Sanford, J. C., Mackie, R. I., Koike, S., Krapac, I. G., Lin, Y. F., Yannarell, A. C., Maxwell, S., & Aminov, R. I. (2009). Fate and transport of antibiotic residues and antibiotic resistance genes following land application of manure waste. Journal of Environmental Quality, 38, 1086â1108.
12. Chopra, I., Hesse, L., & OâNeill, A. (2002). Discovery and development of new anti-bacterial drugs. In Pharmacochemistry Library, Vol. 32, Trends in Drug Research III (ed. H. van der Goot), 213â225. Amsterdam: Elsevier.
13. Clatworthy, A. E., Pierson, E., & Hung, D. T. (2007). Targeting virulence: a new paradigm for antimicrobial therapy. Nature Chemical Biology, 3, 541â548.
14. Cook, M., Molto, E., & Anderson, C. (1989). Fluorochrome labelling in Roman period skeletons from Dakhleh Oasis, Egypt. American Journal of Physical Anthropology, 80, 137â143.
15. Cui, L., & Su, X. Z. (2009). Discovery, mechanisms of action and combination therapy of artemisinin. Expert Review of Anti-Infective Therapy, 7, 999â1013.
16. Davies, J., Spiegelman, G. B., & Yim, G. (2006). The world of subinhibitory antibiotic concentrations. Current Opinion in Microbiology, 9, 445â453.
17. de la Cueva-MĂ©ndez, G., & Pimentel, B. (2007). Gene and cell survival: lessons from prokaryotic plasmid R1. EMBO Reports, 8, 458â464.
18. Devasahayam, G., Scheld, W. M., & Hoffman, P. S. (2010). Newer antibacterial drugs for a new century. Expert Opinion on Investigational Drugs, 19, 215â234.
19. Diacon, A. H., Pym, A., & Grobusch, M. (2009). The diarylquinoline TMC207 for multidrug-resistant tuberculosis. New England Journal of Medicine, 360, 2397â2405.
20. Domagk, G. (1935). Ein Beitragzur Chemotherapie der bakteriellen Infektionen. Deutsche Medizinische Wochenschrift, 61, 250.
21. Dubern, J. F., & Diggle, S. P. (2008). Quorum sensing by 2-alkyl-4-quinolones in Pseudomonas aeruginosa and other bacterial species. Molecular Biosystems, 4, 882â888.22. Ehrlich, P., & Hata, S. (1910). Die Experimentelle Chemotherapie der Spirilosen. Berlin: Julius Springer.
23. Emmerich, R., & Löw, O. (1899). Bakteriolytische enzyme als Ursache der erworbenen ImmunitĂ€t und die Heilung von Infectionskrankheiten durch dieselben. Zeitschrift fĂŒr Hygiene und Infektionskrankheiten, 31, 1â65.
24. Enne, V. I., Bennett, P. M., Livermore, D. M., & Hall, L. M. (2004). Enhancement of host fitness by the sul2-coding plasmid p9123 in the absence of selective pressure. Journal of Antimicrobial Chemotherapy, 53, 958â963.
25. European Centre for Disease Prevention and Control/European Medicines Agency Joint Working Group (ECDC/EMEA). (2009). The Bacterial Challenge: Time to React. Available at www.ecdc.europa.eu/en/publications/Publications/0909_TER_The_Bacterial_Challenge_Time_to_React.pdf.26. Fajardo, A., & MartĂnez, J. L. (2008). Antibiotics as signals that trigger specific bacterial responses. Current Opinion in Microbiology, 11, 161â167.
27. Falkinham, J. O. 3rd, Wall, T. E., Tanner, J. R., Tawaha, K., Alali, F. Q., Li, C., & Oberlies, N. H. (2009). Proliferation of antibiotic-producing bacteria and concomitant antibiotic production as the basis for the antibiotic activity of Jordan's red soils. Applied and Environmental Microbiology, 75, 2735â2741.
28. Fevre, C., Jbel, M., Passet, V., Weill, F. X., Grimont, P. A., & Brisse, S. (2005). Six groups of the OXY ÎČ-lactamase evolved over millions of years in Klebsiella oxytoca. Antimicrobial Agents and Chemotherapy, 49, 3453â3462.
29. Fleming, A. (1929). On antibacterial action of culture of Penicillium, with special reference to their use in isolation of B. influenzae. British Journal of Experimental Pathology, 10, 226â236.
30. Garau, G., Di Guilmi, A. M., & Hall, B. G. (2005). Structure-based phylogeny of the metallo-beta-lactamases. Antimicrobial Agents and Chemotherapy, 49, 2778â2784.
31. Garriss, G., Waldor, M. K., & Burrus, V. (2009). Mobile antibiotic resistance encoding elements promote their own diversity. PLoS Genetics, 5, e1000775. doi: 10.1371/journal.pgen.1000775.
32. Gartin, M., Brewis, A. A., & Schwartz, N. A. (2010). Nonprescription antibiotic therapy: cultural models on both sides of the counter and both sides of the border. Medical Anthropology Quarterly, 24, 85â107.
33. Goossens, H., Ferech, M., Vander Stichele, R., Elseviers, M., & ESAC Project Group. (2005). Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. The Lancet, 365, 579â587.
34. Gotoh, Y., Eguchi, Y., Watanabe, T., Okamoto, S., Doi, A., & Utsumi, R. (2010). Two-component signal transduction as potential drug targets in pathogenic bacteria. Current Opinion in Microbiology, 13, 232â239.
35. Griffin, M. O., Fricovsky, E., Ceballos, G., & Villarreal, F. (2010). Tetracyclines: a pleiotropic family of compounds with promising therapeutic properties. Review of the literature. American Journal of Physiology - Cell Physiology, 299, C539âC548.
36. Grigoryan, L., Burgerhof, J. G., Degener, J. E., Deschepper, R., Lundborg, C. S., Monnet, D. L., Scicluna, E. A., Birkin, J., Haaijer-Ruskamp, F. M., & SAR Consortium. (2007). Attitudes, beliefs and knowledge concerning antibiotic use and self-medication: a comparative European study. Pharmacoepidemiology and Drug Safety, 16, 1234â1243.
37. Hall, B. G., & Barlow, M. (2004). Evolution of the serine beta-lactamases: past, present and future. Drug Resistance Updates, 7, 111â123.38. Hancock, R. E., & Sahl, H. G. (2006). Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nature Biotechnology, 24, 1551â1557.
39. Hays, E. E., Wells, I. C., Katzman, P. A., Cain, C. K., Jacobs, F. A., Thayer, S. A., Doisy, E. A., Gaby, W. L., Roberts, E. C., Muir, R. D., Carroll, C. J., Jones, L. R., & Wade, N. J. (1945). Antibiotic substances produced by Pseudomonas aeruginosa. Journal of Biological Chemistry, 159, 725â750.
40. Hegde, S. S., Vetting, M. W., Roderick, S. L., Mitchenall, L. A., Maxwell, A., Takiff, H. E., & Blanchard, J. S. (2005). A fluoroquinolone resistance protein from Mycobacterium tuberculosis that mimics DNA. Science, 308, 1480â1483.
41. Hegreness, M., Shoresh, N., Damian, D., Hartl, D., & Kishony, R. (2008). Accelerated evolution of resistance in multidrug environments. Proceedings of the National Academy of Sciences of the United States of America, 105, 13977â13981.
42. Hughes, C. C., & Fenical, W. (2010). Antibacterials from the sea. Chemistry, 16, 12512â12525.43. Kaufmann, G. F., Sartorio, R., Lee, S. H., Rogers, C. J., Meijler, M. M., Moss, J. A., Clapham, B., Brogan, A. P., Dickerson, T. J., & Janda, K. D. (2005). Revisiting quorum sensing: discovery of additional chemical and biological functions for 3-oxo-N-acylhomoserine lactones. Proceedings of the National Academy of Sciences of the United States of America, 102, 309â314.
44. Keller, M. A., & Stiehm, E. R. (2000). Passive immunity in prevention and treatment of infectious diseases. Clinical Microbiology Reviews, 13, 602â614.
45. Kobayashi, T., Nonaka, L., Maruyama, F., & Suzuki, S. (2007). Molecular evidence for the ancient origin of the ribosomal protection protein that mediates tetracycline resistance in bacteria. Journal of Molecular Evolution, 65, 228â235.
46. Kohanski, M. A., Dwyer, D. J., & Collins, J. J. (2010a). How antibiotics kill bacteria: from targets to networks. Nature Reviews Microbiology, 8, 423â435.
47. Kohanski, M. A., DePristo, M. A., & Collins, J. J. (2010b). Sublethal antibiotic treatment leads to multidrug resistance via radical-induced mutagenesis. Molecular Cell, 37, 311â320.
48. Kumarasamy, K. K., Toleman, M. A., Walsh, T. R., Bagaria, J., Butt, F., Balakrishnan, R., Chaudhary, U., Doumith, M., Giske, C. G., & Irfan, S. (2010). Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. The Lancet Infectious Diseases, 10, 597â602.
49. Lee, H. H., Molla, M. N., Cantor, C. R., & Collins, J. J. (2010). Bacterial charity work leads to population-wide resistance. Nature, 467, 82â85.
50. Levin, B. R., & Bull, J. J. (2004). Population and evolutionary dynamics of phage therapy. Nature Reviews Microbiology, 2, 166â173.
51. Lloyd, N. C., Morgan, H. W., Nicholson, B. K., & Ronimus, R. S. (2005). The Composition of Ehrlich's Salvarsan: resolution of a century-old debate. Angewandte Chemie International Edition, 44, 941â944.
52. Lock, R. L., & Harry, E. J. (2008). Cell-division inhibitors: new insights for future antibiotics. Nature Reviews Drug Discovery, 7, 324â338.
53. Lomovskaya, O., & Bostian, K. A. (2006). Practical applications and feasibility of efflux pump inhibitors in the clinic--a vision for applied use. Biochemical Pharmacology, 71, 910â918.
54. Lu, T. K., & Collins, J. J. (2009). Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy. Proceedings of the National Academy of Sciences of the United States of America, 106, 4629â4633.